Skip to main content

Clinical Trials Using Avelumab

Review the clinical trials studying avelumab on this list and use the filters to refine the results by age and location. Some clinical trials are held at NCI-Designated Cancer Centers and may be supported by other organizations.

You can find more information about the types and phases of clinical trials and what to expect or use our Steps to Find a Clinical Trial.

Trials 1-19 of 19

Comparing the Outcome of Immunotherapy-Based Drug Combination Therapy with or without Surgery to Remove the Kidney in Metastatic Kidney Cancer, the PROBE Trial
Status: Active
Location: 441 locations
Testing the Addition of Stereotactic Radiation Therapy with Immune Therapy for the Treatment of Patients with Unresectable or Metastatic Renal Cell Cancer, SAMURAI Trial
Status: Active
Location: 264 locations
Testing the Combination of two Anticancer Drugs M1774 (Tuvusertib) and Avelumab to Evaluate their Safety and Effectiveness in Treating Merkel Cell Skin Cancer, MATRiX Trial
Status: Active
Location: 51 locations
Testing the Combination of New Anti-cancer Drug Peposertib with Avelumab and Radiation Therapy for Advanced/Metastatic Solid Tumors and Hepatobiliary Malignancies
Status: Active
Location: 43 locations
Avelumab with Binimetinib, Sacituzumab Govitecan, or Liposomal Doxorubicin in Treating Patients with Stage IV or Unresectable, Recurrent Triple Negative Breast Cancer
Status: Active
Location: 13 locations
Radiation Medication (Radium-223 dichloride) versus Radium-223 dichloride plus Radiation Enhancing Medication (M3814) versus Radium-223 dichloride plus M3814 plus Avelumab (a type of immunotherapy) for Advanced Prostate Cancer Not Responsive to Hormonal Therapy
Status: Active
Location: 18 locations
Avelumab or Hydroxychloroquine with or without Palbociclib for the Treatment of Stage II-III Breast Cancer, PALAVY Study
Status: Active
Location: 8 locations
Study of Sacituzumab Govitecan in Participants With Urothelial Cancer That Cannot Be Removed or Has Spread
Status: Active
Location: 16 locations
Study of AU-007, A Monoclonal Antibody That Binds to IL-2 and Inhibits IL-2Rα Binding, in Patients With Unresectable Locally Advanced or Metastatic Cancer
Status: Active
Location: 3 locations
Avelumab with M1774 for the Treatment of Patients with ARID1A-Mutated Recurrent Endometrial Cancer who have Received Prior Immunotherapy
Status: Active
Location: 2 locations
Immune Checkpoint Inhibitors with or without Propranolol Hydrochloride for the Treatment of Urothelial Cancer
Status: Active
Location: 2 locations
Navtemadlin (KRT-232) With or Without Anti-PD-1/Anti-PD-L1 for the Treatment of Patients With Merkel Cell Carcinoma
Status: Active
Location: 2 locations
A Microdevice for Candidate Drug Screening in Patients with Skin Squamous Cell Carcinoma
Status: Active
Location: 2 locations
Comparing Length of Treatment with Immunotherapy in Patients with Advanced Solid Tumors
Status: Active
Location: University of Pittsburgh Cancer Institute (UPCI), Pittsburgh, Pennsylvania
Lurbinectedin With or Without Avelumab in Small Cell Carcinoma of the Bladder (LASER)
Status: Active
Location: National Institutes of Health Clinical Center, Bethesda, Maryland
Study of 225Ac-SS0110 in Subjects With ES-SCLC or MCC (SANTANA-225 )
Status: Active
Location: See ClinicalTrials.gov
Pemetrexed and Avelumab in Treating Patients with MTAP-Deficient Metastatic Urothelial Cancer
Status: Temporarily Closed to Accrual
Location: M D Anderson Cancer Center, Houston, Texas
Avelumab, Utomilumab, Anti-OX40 Antibody PF-04518600, and Radiation Therapy in Treating Patients with Advanced Malignancies
Status: Temporarily Closed to Accrual and Intervention
Location: See ClinicalTrials.gov
Biomarker-Driven Therapy and Immunotherapy in Screening Participants with Recurrent or Stage IV Non-Small Cell Lung Cancer (The Expanded Lung-MAP Screening Trial)
Status: Active
Location: 1113 locations